A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal
A phase 1/2 trial of PM8002, Ipilimumab, Cabozantinib in renal cell carcinoma, run by Bristol-Myers Squibb, now recruiting.
Overview
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) is a phase 1/2 interventional study registered as NCT07293351 by Bristol-Myers Squibb, with 474 participants planned, started 2026-03-26 and due to reach its primary completion in 2029-11-28. Interventions recorded: Pumitamig, Ipilimumab, Cabozantinib, Casdatifan. Conditions listed: Advanced Renal Cell Carcinoma (RCC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unres
Shares PM8002, Ipilimumab, Bristol Myers Squibb.
- TrialA Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
Shares Ipilimumab, Bristol Myers Squibb, Renal cell carcinoma.
- TrialCOSMIC-313
Shares Cabozantinib, Ipilimumab, Renal cell carcinoma.
- TrialA Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
Shares PM8002, Bristol Myers Squibb.
- TrialA Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung
Shares PM8002, Bristol Myers Squibb.
- TrialA Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
Shares Cabozantinib, Renal cell carcinoma.
- TargetAXL
Shares Cabozantinib, Renal cell carcinoma.
- TrialStudy of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Shares Cabozantinib, Renal cell carcinoma.